111331 ⎘
ssRNA viruses positive-sense; Details; Flaviviridae; Flavivirus, e.g. yellow fever virus, dengue, JEV Demonstrated effect
USE OF DENGUE VACCINE IN PREGNANT AND/OR BREASTFEEDING SUBJECTS
#2MICELLE COMPRISING AMPHIPHILIC PEPTIDE, AND ANTIGEN CARRIER NANOPARTICLE USING SAME
#3COMBINATION THERAPY OF ONCOLYTIC VIRUS DRUGS FOR CANCER TREATMENT
#4ONCOLYTIC VIRUSES AND METHODS OF USE
#5Multi-Epitope Vaccine Platform
#6VIRUS
#7E PROTEIN-MUTATED WEST NILE VIRUS USED AS LIVEATTENUATED VACCINE AND ONCOLYTIC DRUG FOR CANCER THERAPY
#8DEOPTIMIZED YELLOW FEVER VIRUS AND METHODS AND USES THEREOF
#9INORGANIC POLYATOMIC OXYANIONS FOR PROTECTING AGAINST ANTIGENIC DAMAGE DURING PATHOGEN INACTIVATION FOR VACCINE PRODUCTION
#10Universal vaccine platform
#11Inactivating pathogens and producing highly immunogenic inactivated vaccines using a dual oxidation process
#12A LIVE AND ATTENUATED FLAVIVIRUS COMPRISING A MUTATED M PROTEIN
#13CHIMERIC FILOVIRUS VACCINES
#14RESURFACED DENGUE VIRUS AND ZIKI VIRUS GLYCOPROTEIN E DIII VARIANTS AND USES THEREOF
#15METHODS AND COMPOSITIONS FOR STABILIZED RECOMBINANT FLAVIVIRUS E PROTEIN DIMERS
#16Inactivating pathogens and producing highly immunogenic inactivated vaccines using a dual oxidation process
#17PHARMACEUTICAL COMPOSITION CONTAINING STABILIZED NUCLEIC ACID ADJUVANT
#18Zika Virus Constructs and Therapeutic Compositions Thereof
#19Chimeric Zika-Japanese Encephalitis Virus
#20Neutralising antibody against dengue for use in a method of prevention and/or treatment of Zika infection
#21Optimized Zika virus envelope gene and expression thereof
#22Universal vaccine platform
#23Mature virus-like particles of flaviviruses
#24Zika virus immunogenic compositions
#25Inorganic polyatomic oxyanions for protecting against antigenic damage during pathogen inactivation for vaccine production
#26COMPOSITIONS AND METHODS FOR COMBINATION THERAPY WITH DENGUE VIRUS AND DENDRITIC CELLS
#27Recombinant vectors encoding Zika virus protein subunits
#28Methods for generating a Zikv immune response utilizing a recombinant modified vaccina Ankara vector encoding the NS1 protein
#29Lipid nanoparticle vaccine adjuvants and antigen delivery systems
#30COMPOSITIONS AND METHODS FOR PRODUCING DENDRITIC CELLS
#31Lentiviral vector-based Japanese encephalitis immunogenic composition
#32DNA vaccine against virus of Yellow Fever
#33Dengue virus e-glycoprotein polypeptides containing mutations that eliminate immunodominant cross-reactive epitopes
#34Inactivating pathogens and producing highly immunogenic inactivated vaccines using a dual oxidation process
#35Attenuated mutant dengue viruses comprising a mutation in the NS5 non-structural protein
#36Epitope-substituted vaccine for use in improving safety and immunogenicity against dengue viruses
#37Zika virus vaccines
#38Virus
#39Universal vaccine platform
#40Neutralising antibody against dengue for use in a method of prevention and/or treatment of zika infection
#41Zika virus vaccine
#42Compositions and methods for combination therapy with dengue virus and dendritic cells
#43DNA antibody constructs encoding anti-ZIKV envelope antibodies
#44Inorganic polyatomic oxyanions for protecting against antigenic damage during pathogen inactivation for vaccine production
#45Protective anti-ZIKV vaccine without inducing cross-reactions with dengue
#46ZIKA VIRUS VACCINE AND COMBINATION VACCINE
#47Compositions, methods and uses for dengue virus serotype-4 constructs
#48Compositions and methods for combination therapy with dengue virus and dendritic cells
#49METHODS AND COMPOSITIONS FOR ZIKA VIRUS VACCINES
#50DNA vaccine against virus of Yellow Fever
#51Immune enhancing recombinant dengue protein
#52Dengue virus e-glycoprotein polypeptides containing mutations that eliminate immunodominant cross-reactive epitopes
#53Stable live attenuated recombinant dengue vaccine
#54CDNA clone-launched platform for high-yield production of inactivated zika virus
#55Concomitant dengue and yellow fever vaccination
#56Vaccine combination against multiple dengue virus serotypes and preparation and application thereof
#57Thermostable vaccines based on ether lipids and native viral envelope proteins
#58Compositions and methods for combination therapy with dengue virus and dendritic cells
#59Epitope-substituted vaccine for use in improving safety and immunogenicity against dengue viruses
#60Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses
#61Dengue virus vaccine compositions and methods of use thereof
#62METHOD FOR THE PRODUCTION OF RECOMBINANT VIRUS, DNA CONSTRUCTS, RECOMBINANT VIRUS AND VACCINE COMPOSITIONS
#63Methods and compositions for recombinant dengue viruses for vaccine and diagnostic development
#64Lentiviral vector-based Japanese encephalitis immunogenic composition
#65Compositions and methods for combination therapy with dengue virus and dendritic cells
#66Method for the production of recombinant virus, DNA constructs, recombinant virus and vaccine compositions
#67Chimeric poly peptides and the therapeutic use thereof against a flaviviridae infection
#68Compositions and methods for producing dendritic cells
#69West Nile Virus vaccine
#70Compositions, methods and uses for dengue virus serotype-4 constructs
#71Immune enhancing recombinant dengue protein
#72Compositions and methods for combination therapy with dengue virus and dendritic cells
#73Dengue virus E-glycoprotein polypeptides containing mutations that eliminate immunodominant cross-reactive epitopes
#74Lipid nanoparticle vaccine adjuvants and antigen delivery systems
#75DNA vaccine against virus of Yellow Fever
#76Vaccine compositions and uses thereof
#77Novel Flavivirus Antigens
#78Recombinant subunit dengue virus vaccine
#79Recombinant dengue virus antigen comprising the capsid protein leader sequence, full-length prM protein, and full-length E protein
#80VACCINATION AGAINST JAPANESE ENCEPHALITIS, MEASLES, MUMPS AND RUBELLA
#81Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes and methods for their use
#82Chimeric poly peptides and the therapeutic use thereof against a Flaviviridae infection
#83Attenuated mutant dengue viruses comprising a mutation in the NS4B non-structural protein
#84Universal dengue virus sequences and methods of use
#85DNA vaccine against virus of yellow fever
#86Recombinant dengue virus antigen comprising the capsid protein leader sequence, full-length prM protein, and full-length E protein
#87Chimeric poly peptides and the therapeutic use thereof against a flaviviridae infection
#88RECOMBINANT SUBUNIT WEST NILE VIRUS VACCINE FOR PROTECTION OF HUMAN SUBJECTS
#89Recombinant attenuated dengue viruses comprising mutations in NS5 and the 3′ untranslated region
#90Flavivirus host-range mutations and uses thereof
#91West Nile Virus vaccine
#92Recombinant bicistronic flaviviruses and methods of use thereof
#93Deletion mutants of flagellin and methods of use
#94Lentiviral vector-based vaccine
#95Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes and methods for their use
#96Method for the production of recombinant virus, DNA constructs, recombinant virus and vaccine compositions
#97Chimeric poly peptides and the therapeutic use thereof against a Flaviviridae infection
#98Lentiviral vector-based vaccine
#99Nucleic acids encoding novel chimeric C15/prM/E dengue virus immunogens prepared by DNA shuffling
#100Recombinant attenuated dengue viruses comprising a deletion in the 3′ untranslated region and additional attenuating mutations induced by chemical mutagenesis
#101Recombinant dengue virus antigens comprising the C15 signal peptide, full-length PRM protein, and full-length E protein
#102Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes and methods for their use
#103Attenuated dengue virus comprising mutations in the NS3 gene
#104Lentiviral vector-based vaccine
#105Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses